Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate: A Southwest Oncology Group study

M. E. Marshall, B. Blumenstein, E. D. Crawford, I. M. Thompson, J. B. Craig, M. Eisenberger, F. Ahmann

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Amonafide (benzisoquinolinedione; NSC 308847) was subjected to a Phase II trial for the treatment of advanced hormone-refractory carcinoma of the prostate. In addition to adequate baseline organ functions, patients were required to have a favorable performance status, bidimensionally measurable disease and no prior chemotherapy. Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days. Treatment cycles were repeated every 21 days. Dose escalation and reduction schema were used based upon toxicities from preceding cycles. Of 47 patients enrolled, 43 were evaulable. The most common toxicities were hematologic to include leukopenia (72%), granulocytopenia (32.6%), and thrombocytopenia (44.2%). There were no complete responses and only 5 partial responses for an overall response rate of 12% (95% confidence interval: 4-25%). The results indicate that Amonafide, in the dose and schedule tested, lacks sufficient activity against hormone- refractory prostate cancer to warrant further trials.

Original languageEnglish (US)
Pages (from-to)514-515
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume17
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

amonafide
Prostate
Carcinoma
Hormones
Therapeutics
Agranulocytosis
Leukopenia
Thrombocytopenia
Prostatic Neoplasms
Appointments and Schedules
Confidence Intervals
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Marshall, M. E., Blumenstein, B., Crawford, E. D., Thompson, I. M., Craig, J. B., Eisenberger, M., & Ahmann, F. (1994). Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate: A Southwest Oncology Group study. American Journal of Clinical Oncology: Cancer Clinical Trials, 17(6), 514-515.

Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate : A Southwest Oncology Group study. / Marshall, M. E.; Blumenstein, B.; Crawford, E. D.; Thompson, I. M.; Craig, J. B.; Eisenberger, M.; Ahmann, F.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 17, No. 6, 1994, p. 514-515.

Research output: Contribution to journalArticle

Marshall, ME, Blumenstein, B, Crawford, ED, Thompson, IM, Craig, JB, Eisenberger, M & Ahmann, F 1994, 'Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate: A Southwest Oncology Group study', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 17, no. 6, pp. 514-515.
Marshall, M. E. ; Blumenstein, B. ; Crawford, E. D. ; Thompson, I. M. ; Craig, J. B. ; Eisenberger, M. ; Ahmann, F. / Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate : A Southwest Oncology Group study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1994 ; Vol. 17, No. 6. pp. 514-515.
@article{2dad59d21ddd42b3b0bc5034df1f0344,
title = "Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate: A Southwest Oncology Group study",
abstract = "Amonafide (benzisoquinolinedione; NSC 308847) was subjected to a Phase II trial for the treatment of advanced hormone-refractory carcinoma of the prostate. In addition to adequate baseline organ functions, patients were required to have a favorable performance status, bidimensionally measurable disease and no prior chemotherapy. Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days. Treatment cycles were repeated every 21 days. Dose escalation and reduction schema were used based upon toxicities from preceding cycles. Of 47 patients enrolled, 43 were evaulable. The most common toxicities were hematologic to include leukopenia (72{\%}), granulocytopenia (32.6{\%}), and thrombocytopenia (44.2{\%}). There were no complete responses and only 5 partial responses for an overall response rate of 12{\%} (95{\%} confidence interval: 4-25{\%}). The results indicate that Amonafide, in the dose and schedule tested, lacks sufficient activity against hormone- refractory prostate cancer to warrant further trials.",
author = "Marshall, {M. E.} and B. Blumenstein and Crawford, {E. D.} and Thompson, {I. M.} and Craig, {J. B.} and M. Eisenberger and F. Ahmann",
year = "1994",
language = "English (US)",
volume = "17",
pages = "514--515",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate

T2 - A Southwest Oncology Group study

AU - Marshall, M. E.

AU - Blumenstein, B.

AU - Crawford, E. D.

AU - Thompson, I. M.

AU - Craig, J. B.

AU - Eisenberger, M.

AU - Ahmann, F.

PY - 1994

Y1 - 1994

N2 - Amonafide (benzisoquinolinedione; NSC 308847) was subjected to a Phase II trial for the treatment of advanced hormone-refractory carcinoma of the prostate. In addition to adequate baseline organ functions, patients were required to have a favorable performance status, bidimensionally measurable disease and no prior chemotherapy. Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days. Treatment cycles were repeated every 21 days. Dose escalation and reduction schema were used based upon toxicities from preceding cycles. Of 47 patients enrolled, 43 were evaulable. The most common toxicities were hematologic to include leukopenia (72%), granulocytopenia (32.6%), and thrombocytopenia (44.2%). There were no complete responses and only 5 partial responses for an overall response rate of 12% (95% confidence interval: 4-25%). The results indicate that Amonafide, in the dose and schedule tested, lacks sufficient activity against hormone- refractory prostate cancer to warrant further trials.

AB - Amonafide (benzisoquinolinedione; NSC 308847) was subjected to a Phase II trial for the treatment of advanced hormone-refractory carcinoma of the prostate. In addition to adequate baseline organ functions, patients were required to have a favorable performance status, bidimensionally measurable disease and no prior chemotherapy. Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days. Treatment cycles were repeated every 21 days. Dose escalation and reduction schema were used based upon toxicities from preceding cycles. Of 47 patients enrolled, 43 were evaulable. The most common toxicities were hematologic to include leukopenia (72%), granulocytopenia (32.6%), and thrombocytopenia (44.2%). There were no complete responses and only 5 partial responses for an overall response rate of 12% (95% confidence interval: 4-25%). The results indicate that Amonafide, in the dose and schedule tested, lacks sufficient activity against hormone- refractory prostate cancer to warrant further trials.

UR - http://www.scopus.com/inward/record.url?scp=0027973415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027973415&partnerID=8YFLogxK

M3 - Article

C2 - 7977172

AN - SCOPUS:0027973415

VL - 17

SP - 514

EP - 515

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -